PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)
Sponsor: Canadian Institutes of Health Research (CIHR)
A PHASE3 clinical study on Stroke, this trial is ongoing. The trial is conducted by Canadian Institutes of Health Research (CIHR) and has accumulated 11 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Unknown PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Unknown PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Canadian Institutes of Health Research (CIHR)
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .